A novel mutation (F227L) arises in the reverse transcriptase of human immunodeficiency virus type 1 on dose-escalating treatment of HIV type 1-infected cell cultures with the nonnucleoside reverse transcriptase inhibitor thiocarboxanilide UC-781.

Journal article

Treatment of wild-type human immunodeficiency virus [HIV-1(IIIB)]-infected cell cultures with the thiocarboxanilide UC-781 under low selective pressure (i.e., 0.01 microg/ml) resulted in the emergence of V106A RT mutant virus. On increasing drug concentrations (stepwise up to 30 microg/ml) the virus retained the V106A RT mutation but acquired the novel F227L mutation in the RT genome in addition to the L100I, K1O1I, and Y181C mutations. This multiple-mutant virus proved highly resistant to vi...

Expand abstract

Authors: Balzarini, J; Pelemans, H; Esnouf, R; De Clercq, E

• Publication status: Published
• Journal: AIDS research and human retroviruses
• Volume: 14
• Issue: 3
• Pages: 255-260
• Publication date: 1998-02-01
• DOI: 10.1089/aid.1998.14.255
• EISSN: 1931-8405
• ISSN: 0889-2229
• Language: English
• Keywords: Dose-Response Relationship, Drug; Genes, Viral; Evolution, Molecular; HIV Reverse Transcriptase; Tumor Cells, Cultured; Furans; Anilides; Drug Resistance, Microbial; Mutation; Anti-HIV Agents; Humans; Reverse Transcriptase Inhibitors; HIV-1; Microbial Sensitivity Tests